UPMC

Predictive Oncology Announces Positive Results from Ovarian Cancer Study with UPMC Magee-Womens Hospital to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
火曜日, 5月 28, 2024
Patient, Survival, Chair, Intelligence, Translational medicine, Ovarian cancer, UPMC Magee-Womens Hospital, Machine learning, Disease, Senior, MD, AI, Oncology, Cancer, Medical director, Gynaecology, Drug discovery, ASCO, Biomarker, Professor, UPMC, Hospital, Society, Reproductive Sciences, Survivor, Annual general meeting

PITTSBURGH, May 28, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that positive results from a retrospective study that the company recently completed in collaboration with UPMC Magee-Womens Hospital will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held May 31-June 4, 2024, in Chicago, Il.

Key Points: 
  • PITTSBURGH, May 28, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that positive results from a retrospective study that the company recently completed in collaboration with UPMC Magee-Womens Hospital will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held May 31-June 4, 2024, in Chicago, Il.
  • The purpose of the study was to determine if Predictive Oncology could leverage its artificial intelligence and other capabilities to develop machine learning (ML) models that could more accurately predict both short-term (two-year) and long-term (five-year) survival outcomes among ovarian cancer patients.
  • “We believe these results highlight the potential of AI and machine learning to not only accelerate early oncology drug discovery, but to assist with the clinical management of cancer patients in real-time, thereby improving survival outcomes.
  • We also see an opportunity to leverage these findings to discover unique biomarkers that can be used by us or a partner to develop novel cancer therapeutics.

Predictive Oncology Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
水曜日, 5月 15, 2024
Patient, Survival, GMP, Holocene, Intelligence, Ovarian cancer, Science, Machine learning, HGSC, Solubility, CDT, EDT, Drug development, CLIA, Call, Conference, Marketing, Fujifilm, Research, Drug discovery, Biomarker, ASCO, Depreciation, UPMC Magee-Womens Hospital, UPMC, Hospital, Woman, Society, Therapy, Annual general meeting, Pharmaceutical industry

The company reported a net loss of approximately $4.2 million on total revenue of approximately $0.4 million for the quarter.

Key Points: 
  • The company reported a net loss of approximately $4.2 million on total revenue of approximately $0.4 million for the quarter.
  • General and administrative expenses increased to $2,627,076 in the first quarter of 2024 from $2,335,984 in the first quarter of 2023.
  • Operations expenses increased to $1,102,193 in the first quarter of 2024 compared to $878,518 in the first quarter of 2023.
  • Sales and marketing expenses increased to $739,734 in the first quarter of 2024 from $370,237 in the first quarter of 2023.

Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site

Retrieved on: 
月曜日, 5月 20, 2024
Other Health, Research, Managed Care, General Health, Pharmaceutical, Oncology, Health Technology, Clinical Trials, Science, Biotechnology, Other Science, Health, Clinical research, Patient, University, UPMC Hillman Cancer Center, Immunotherapy, Lung cancer, Drug development, NSCLC, FACP, MD, GDT, Associate, UPMC, OTCQB, National Cancer Institute, NCI-designated Cancer Center, Pharmaceutical industry

Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) announces that UPMC in Pittsburgh, Pennsylvania has been activated as the fourth clinical trial site in the Deltacel-01 Phase 1 trial evaluating Deltacel™ (KB-GDT-01), Kiromic’s allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC).

Key Points: 
  • Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) announces that UPMC in Pittsburgh, Pennsylvania has been activated as the fourth clinical trial site in the Deltacel-01 Phase 1 trial evaluating Deltacel™ (KB-GDT-01), Kiromic’s allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small cell lung cancer (NSCLC).
  • UPMC is a world-renowned healthcare system that employs some of the nation’s top clinicians and medical researchers.
  • The lead principal investigator for Deltacel-01, Jason J. Luke, MD, FACP, will also serve as principal investigator at the UPMC site.
  • We expect to activate one more clinical trial site later this quarter and to begin enrolling patients at UPMC this summer,” said Pietro Bersani, Chief Executive Officer of Kiromic.

Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
木曜日, 5月 9, 2024
Mortality, FDA, Research and development, TEL, Systemic scleroderma, Nature, Capital, Publication, CMMB, Primary sclerosing cholangitis, European Patent Convention, Research, Communication, Proteomics, Digestate, MD, Doctor of Philosophy, Liver, UPMC, Administration, PSC, Disease, Therapy, Patent, Risk, Patient, Scleroderma, Diagnosis, Biomarker, Clinical trial, CCL24, UC, Pharmaceutical industry

TEL AVIV, Israel, May 09, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq:CMMB), (Chemomab), a clinical-stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced financial and operating results for the first quarter ended March 31, 2024, and provided a corporate update.

Key Points: 
  • (Nasdaq:CMMB), (Chemomab), a clinical-stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced financial and operating results for the first quarter ended March 31, 2024, and provided a corporate update.
  • In January, 2024, Chemomab reported publication of new proteomics research in the peer-reviewed journal Cells reinforcing the clinical potential of CM-101 in primary sclerosing cholangitis.
  • Research and Development (R&D) Expenses: R&D expenses were $3.1 million for the first quarter of 2024, compared to $6.9 million for the first quarter of 2023.
  • General and Administrative (G&A) Expenses: G&A expenses were $0.9 million for the first quarter of 2024, compared to $2.2 million for the first quarter of 2023.

Abridge and UChicago Medicine to Collaborate on Research Using AI-Generated Clinical Conversation Data

Retrieved on: 
木曜日, 5月 9, 2024
Technology, Health Technology, Telemedicine, Virtual Medicine, Software, Practice Management, Biometrics, Health, Data Management, Artificial Intelligence, University, Emory Healthcare, News, Sutter Health, Research, UPMC, Patient, Pharmaceutical industry

UChicago Medicine is focused on improving clinician wellness and transforming the patient experience using evidence-based technology.

Key Points: 
  • UChicago Medicine is focused on improving clinician wellness and transforming the patient experience using evidence-based technology.
  • View the full release here: https://www.businesswire.com/news/home/20240509917166/en/
    UChicago Medicine and Abridge will collaborate on research as part of the initial deployment, measuring how Abridge’s Epic-integrated AI platform impacts clinician wellness, retention, and patient outcomes.
  • UChicago Medicine will also serve as a development site for new experimental workflows enabled by Abridge’s co-development relationship with Epic .
  • “We are excited to work with UChicago Medicine, and deploy technology that improves the care delivery experience,” said Dr. Shiv Rao, CEO and Founder of Abridge.

XEALTH NAMED TO NEWSWEEK’S WORLD’S BEST DIGITAL HEALTH COMPANIES 2024 LIST

Retrieved on: 
木曜日, 4月 25, 2024
Online, Statista, Statistica, Roger Hawkins (drummer), Banner Health, Advocate Aurora Health, MCW, Engagement, Statistics, EHR, Research, Baystate, UPMC, Newsweek, Telehealth, Stanford University, Digital health, ChristianaCare, Patient, Treatment, Scripps Health, Data analysis, Mobile phone

SEATTLE, April 25, 2024 (GLOBE NEWSWIRE) -- Xealth , the leader in enabling digital health at scale, today announced that it has been named to Newsweek’s list of the World’s Best Digital Health Companies 2024.

Key Points: 
  • SEATTLE, April 25, 2024 (GLOBE NEWSWIRE) -- Xealth , the leader in enabling digital health at scale, today announced that it has been named to Newsweek’s list of the World’s Best Digital Health Companies 2024.
  • We are excited to be recognized by Newsweek’s World’s Best Digital Health Companies.”
    The World’s Best Digital Health Companies 2024 ranking lists the top 400 companies from over 35 different countries.
  • Xealth has shown deep market traction, with customers including nearly 30 major health systems, such as Advocate Aurora Health, Banner Health, Baystate, Children’s Wisconsin, ChristianaCare, Duke Health, The Froedtert & the MCW health network, Providence, Scripps Health, Southern Illinois Health, Stanford and UPMC.
  • Based on the results of the study, Xealth has been recognized on Newsweek’s World’s Best Digital Health Companies 2024 list.

Predictive Oncology Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
水曜日, 4月 24, 2024
UPMC Magee-Womens Hospital, ASCO, Survival, Annual general meeting, Society, Woman, UPMC, HGSC, Oncology

PITTSBURGH, April 24, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that an abstract has been accepted for presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held May 31-June 4, 2024, in Chicago, Il.

Key Points: 
  • PITTSBURGH, April 24, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that an abstract has been accepted for presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held May 31-June 4, 2024, in Chicago, Il.
  • The abstract highlights results from a recent study that Predictive Oncology completed in collaboration with UPMC Magee-Womens Hospital in Pittsburgh, PA.
  • The study utilized multi-omic machine learning models to determine if they could better predict short- and long-term survival outcomes among women diagnosed with high grade serous ovarian cancer (HGSC) as compared to clinical data alone.

BriaCell Announces Oral and Poster Presentations at ASCO 2024

Retrieved on: 
水曜日, 4月 24, 2024
Wilfrid Sellars, University, Mayo Clinic, Weill Cornell Medicine, University of Miami, Poster, BCT, MD, TSX, Principal investigator, Doctor of Philosophy, Spacecraft, UPMC, McCormick Place, DRS, ASCO, Cornell University, ADC, Patient, Society, Annual general meeting, Therapy, Partner, Pharmaceutical industry

Oral presentation by Mayo Clinic Professor and Principal Investigator, Saranya Chumsri, MD

Key Points: 
  • Oral presentation by Mayo Clinic Professor and Principal Investigator, Saranya Chumsri, MD
    Two poster presentations include Drs.
  • Principal Investigator and Professor of Oncology, Mayo Clinic, Saranya Chumsri, MD, will be giving the presentation.
  • BriaCell will also have two poster presentations.
  • The first poster will describe the Company’s ongoing pivotal Phase 3 registrational study in advanced metastatic breast cancer.

AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

Retrieved on: 
水曜日, 4月 10, 2024
PFS, University, Epithelium, UPMC Magee-Womens Hospital, Pancreatic cancer, Triple-negative breast cancer, Colorectal cancer, Research, Cisplatin, AIM, MD, Peritoneum, Gynecologic Oncology (journal), UPMC, Gynaecology, Disease, Liver, Patient, CXCL10, CXCL11, Reproductive Sciences, Progression-free survival, Data analysis, Neoplasm, Biomarker, CXCL9, Cancer, RNA, Ovarian cancer, Medical imaging

See further details on the study “Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer” at ClinicalTrials.gov: NCT03734692 .

Key Points: 
  • See further details on the study “Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer” at ClinicalTrials.gov: NCT03734692 .
  • Additionally, the immunological signature supporting this synergistic enhancement has been seen in other clinical trials, including with pancreatic cancer ( 1 , 2 ) metastatic triple-negative breast cancer and colorectal cancer metastatic to the liver .
  • Ampligen is a dsRNA product candidate that acts via the TLR-3 receptor present on several immune cells, epithelial cells and most solid tumors.
  • Additionally, Keynote-100’s median PFS was 2.1 months, or significantly less than that seen in the ongoing Ampligen study.

Henry Schein Medical Announces Winner of Its 2024 Rising Star Award

Retrieved on: 
火曜日, 4月 23, 2024
Other Sports, Sports, Fitness & Nutrition, Other Health, Training, General Health, University, Health, Primary, Secondary, Education, Orientation, Organization, Recognition, Anderson High School, Sports medicine, AED, Mentorship, UPMC, Emergency, Buffalo Beauts, Cardiac arrest, Bellport High School, Henry Schein, Athlete, ATC, Multimedia, Newberry High School, MBA, LAT, Rising Star Award, Student, New Rochelle, New York, Mental, Iona University, Monongahela River, Nursing

Henry Schein Medical, the U.S. medical business of Henry Schein, Inc. (Nasdaq: HSIC), announced today that Aline Valiengo, Head Athletic Trainer and Director of Sports Medicine for Coconut Creek High School in Florida, is the winner of the fourth annual Henry Schein Medical Athletics and Schools Rising Star Award .

Key Points: 
  • Henry Schein Medical, the U.S. medical business of Henry Schein, Inc. (Nasdaq: HSIC), announced today that Aline Valiengo, Head Athletic Trainer and Director of Sports Medicine for Coconut Creek High School in Florida, is the winner of the fourth annual Henry Schein Medical Athletics and Schools Rising Star Award .
  • “Winning the 2024 Rising Star Award is more than just recognition, it's a validation of my effort, dedication, and passion I have for this profession,” said Ms. Valiengo.
  • The Rising Star Award program began in 2021 with winner Darlene Eckhardt , Head Athletic Trainer at the Buffalo Beauts, a professional women's ice hockey team, becoming Henry Schein’s first Rising Star.
  • For more information about the Rising Star Award, click here .